Arcus Biosciences, Inc.RCUS财报
NYSE · biotechnology industry
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 35.00% | 31.5M | 无变化 | 2024-01-31 |
| BlackRock, Inc. | 10.60% | 9.7M | 无变化 | 2024-11-08 |
| The Vanguard Group | 6.25% | 4.7M | — | 2024-02-13 |
| FMR LLC | 4.89% | 4.5M | ▼ -1.43pp | 2024-11-12 |
| Terry Rosen, Ph.D. | 4.10% | 3.8M | — | 2024-12-17 |
| STATE STREET CORPORATION | 3.30% | 3.0M | ▼ -2.36pp | 2024-10-17 |
内部人交易
Net 90d: +$0 · buys $0 / sells $0时间范围:
类型:
身份:
没有符合筛选条件的交易。